Evidence map›Paper›PMID 37408796›Full record

ArticleBioactive materials2023

An ischemic area-targeting, peroxynitrite-responsive, biomimetic carbon monoxide nanogenerator for preventing myocardial ischemia-reperfusion injury.

Jinyan Zhang, Liwei Liu, Zhen Dong, Xicun Lu, Wenxuan Hong, Jin Liu, Xiaoyi Zou, Jinfeng Gao, Hao Jiang, Xiaolei Sun and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Jinyan ZhangDepartment of Cardiology, Zhongshan Hospital, Fudan University, China.
Liwei LiuDepartment of Cardiology, Zhongshan Hospital, Fudan University, China.
Zhen DongDepartment of Cardiology, Zhongshan Hospital, Fudan University, China.
Xicun LuState Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China.
Wenxuan HongDepartment of Cardiology, Zhongshan Hospital, Fudan University, China.
Jin LiuDepartment of Cardiology, Zhongshan Hospital, Fudan University, China.
Xiaoyi ZouDepartment of Cardiology, Zhongshan Hospital, Fudan University, China.
Jinfeng GaoDepartment of Cardiology, Zhongshan Hospital, Fudan University, China.
Hao JiangDepartment of Cardiology, Zhongshan Hospital, Fudan University, China.
Xiaolei SunDepartment of Cardiology, Zhongshan Hospital, Fudan University, China.
Kai HuDepartment of Cardiology, Zhongshan Hospital, Fudan University, China.
Youjun YangState Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China.
Junbo GeDepartment of Cardiology, Zhongshan Hospital, Fudan University, China.
Xiao LuoShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
Aijun SunDepartment of Cardiology, Zhongshan Hospital, Fudan University, China.
Fudan University · CNZhongshan Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNEast China University of Science and Technology · CNEast China Normal University · CNShanghai Institute of Hematology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial ischemia-reperfusion (MI/R) injury is common in patients who undergo revascularization therapy for myocardial infarction, often leading to cardiac dysfunction. Carbon monoxide (CO) has emerged as a therapeutic molecule due to its beneficial properties such as anti-inflammatory, anti-apoptotic, and mitochondrial biogenesis-promoting properties. However, its clinical application is limited due to uncontrolled release, potential toxicity, and poor targeting efficiency. To address these limitations, a peroxynitrite (ONOO

Indexed as

InflammationIschemia-reperfusion injuryMacrophage membraneMitochondriaPeroxynitrite

Identifiers

PMID37408796
PMCPMC10318466
OpenAlexW4381987538

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.